Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
FORM 4
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Bristol Myers Squibb is a large pharmaceutical company with a diversified portfolio spanning oncology, immunology, cardiovascular, and neuroscience treatments, currently navigating patent expirations on several legacy blockbuster products.
Business model
The company earns revenue from a broad drug portfolio, with legacy products facing generic competition while newer therapies in oncology and neuroscience represent the primary avenues for offsetting that revenue decline.
Growth drivers
- New product launches in oncology and neuroscience
- Pipeline progress across multiple therapeutic areas
- International expansion of newer therapies
- Cost discipline supporting margins during the transition period
Competitive position
Bristol Myers Squibb's diversified therapeutic area presence and substantial research capabilities support its ability to develop replacement revenue streams, though the timing of that transition remains a key uncertainty.
Risks
Patent expirations on several major products create meaningful near term revenue headwinds, pipeline execution needs to succeed to offset that decline, and generic competition timing adds uncertainty to financial projections.
Valuation
Bristol Myers Squibb trades at a discounted multiple reflecting the ongoing patent cliff challenges, similar to other large pharmaceutical companies navigating major product transitions.
Final view
Bristol Myers Squibb faces a genuine transition period as legacy products face patent expiration. My view is cautious, with pipeline execution in oncology and neuroscience being essential to watch for signs the transition is succeeding.
Overall rating: 56/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.